Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment

Author： Eldar-Finkelman Hagit   Ilouz Ronit  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.9, 2003-09, pp. : 1511-1519

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes

By Eldar-Finkelman Hagit   Kaidanovich Oksana  

Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 5, 2002-10 ,pp. : 555-561

Informa Healthcare

Access to resources Recommend Favorite

Role of Glycogen Synthase Kinase-3 in Insulin Resistance and Type 2 Diabetes

By  

Current Drug Targets, Vol. 7, Iss. 11, 2006-01 ,pp. : 1435-1441

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes

By MacAulay Katrina   Woodgett James R  

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 10, 2008-10 ,pp. : 1265-1274

Informa Healthcare

Access to resources Recommend Favorite

Vertex inhibitors of Aurora-2, glycogen synthase kinase-3 and Src kinase

By  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 3, 2004-03 ,pp. : 439-443

Informa Healthcare

Access to resources Recommend Favorite

Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease

By  

Current Pharmaceutical Design, Vol. 16, Iss. 25, 2010-08 ,pp. : 2790-2798

Bentham Science Publishers

Access to resources Recommend Favorite